This study investigated the role of microRNA-21 (miR-21) and let-7a microRNA in paediatric and adult cholesteatoma. Total RNA and protein were isolated from the cholesteatoma specimens and normal skin of 10 adults and 10 children. Levels of miR-21 and let-7a microRNA were assessed by real-time reverse transcription-polymerase chain reaction, and levels of phosphatase and tensin homologue (PTEN), programmed cell death 4 (PDCD4) and high mobility group AT-hook 2 (HMGA2) protein were assessed by Western blot analysis. Levels of miR-21 and let-7a microRNA were significantly higher in cholesteatoma tissue compared with normal skin, especially in paediatric patients. PTEN, PDCD4 and HMGA2 protein levels were significantly lower in paediatric versus adult cholesteatoma patients. It is possible that upregulation of miR-21 leads to higher tumour cell proliferation and invasion of cholesteatoma in children than adults, and the benign nature of cholesteatoma may be due to a balance between let-7a microRNA and miR-21. These data may help to identify targets for miRNA- and protein-based therapeutic interventions for the non-surgical or adjunctive treatment of cholesteatoma.
JamesALChadhaNKPapsinBC: Pediatric cholesteatoma and variants in the gene encoding connexin 26. Laryngoscope2010; 120: 183–187.
2.
JuhászASziklaiIRákosyZ: Elevated level of tenascin and matrix metalloproteinase 9 correlates with the bone destruction capacity of cholesteatomas. Otol Neurotol2009; 30: 559–565.
3.
KuczkowskiJSakowicz-BurkiewiczMIżycka-ŚwieszewskaE: Expression of tumour necrosis factor-α, interleukin-1α, interleukin-6 and interleukin-10 in chronic otitis media with bone osteolysis. ORL J Otorhinolaryngol Relat Spec2011; 73: 93–99.
4.
HaruyamaTFurukawaMKusunokiT: Expression of IL-17 and its role in bone destruction in human middle ear cholesteatoma. ORL J Otorhinolaryngol Relat Spec2010; 72: 325–331.
5.
Suchozebrska-JesionekDSzymańskiMKurzepaJ: Gelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma. J Otolaryngol Head Neck Surg2008; 37: 628–632.
6.
KuczkowskiJKobierska-GulidaGSwieszewskaE Izycka: Molecular control of bone resorption in chronic otitis media with cholesteatoma. Otolaryngol Pol2010; 64: 219–224 [in Polish, English abstract].
7.
KuczkowskiJSakowicz-BurkiewiczMIżycka-ŚwieszewskaE: Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media. Am J Otolaryngol2010; 31: 404–409.
BujíaJHollyAAntolí-CandelaF: Immunobiological peculiarities of cholesteatoma in children: quantification of epithelial proliferation by MIB 1. Laryngoscope1996; 106: 865–868.
10.
MigirovLCarmelEDaganE: Mastoid subperiosteal abscess as a first sign of unnoticed cholesteatoma in children. Acta Paediatr2010; 99: 147–149.
11.
KimJLJungHH: Proteomic analysis of cholesteatoma. Acta Otolaryngol2004; 124: 783–788.
12.
KwonKHKimSJKimHJ: Analysis of gene expression profiles in cholesteatoma using oligonucleotide microarray. Acta Otolaryngol2006; 126: 691–697.
13.
SongJJChaeSWWooJS: Differential expression of human beta defensin 2 and human beta defensin 3 in human middle ear cholesteatoma. Ann Otol Rhinol Laryngol2007; 116: 235–240.
14.
GhanooniRDecaesteckerCSimonP: Characterization of patterns of expression of protein kinase C-α, -δ, -η, -γ and -ζ and their correlations to p53, galectin-3, the retinoic acid receptor-β and the macrophage migration inhibitory factor (MIF) in human cholesteatomas. Hear Res2006; 214: 7–16.
15.
MaciasMPGerkinRDMaciasJD: Increased amphiregulin expression as a biomarker of cholesteatoma activity. Laryngoscope2010; 120: 2258–2263.
16.
BartelDP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell2004; 116: 281–297.
17.
HuiABLenarduzziMKrushelT: Comprehensive microRNA profiling for head and neck squamous cell carcinomas. Clin Cancer Res2010; 16: 1129–1139.
18.
DjuranovicSNahviAGreenR: A parsimonious model for gene regulation by miRNAs. Science2011; 331: 550–553.
19.
NohataNSoneYHanazawaT: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget2011; 2: 29–44.
20.
GordanpourAStanimirovicANamRK: miR-221 is down-regulated in TMPRSS2: ERG fusion-positive prostate cancer. Anticancer Res2011; 31: 403–410.
21.
MoriyamaTOhuchidaKMizumotoK: MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther2009; 8: 1067–1074.
22.
HiyoshiHKamoharaHKarashimaR: MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res2009; 65: 1915–1922.
23.
FabjaniGTongDWolfA: HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep2005; 14: 737–741.
24.
MotoyamaKInoueHNakamuraY: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res2008; 14: 2334–2340.
25.
FriedlandDREernisseRErbeC: Cholesteatoma growth and proliferation: posttranscriptional regulation by microRNA-21. Otol Neurotol2009; 30: 998–1005.
26.
SajALaiEC: Control of microRNA biogenesis and transcription by cell signaling pathways. Curr Opin Genet Dev2011; 21: 504–510.
27.
ZhuSWuHWuF: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res2008; 18: 350–359.
28.
MengFHensonRJanekH Wehbe: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology2007; 133: 647–658.
29.
FrankelLBChristoffersenNRJacobsenA: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem2008; 283: 1026–1033.
30.
EdwinFSinghREndersbyR: The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem2006; 281: 4816–4822.
SuzukiANakanoTMakTW: Portrait of PTEN: messages from mutant mice. Cancer Sci2008; 99: 209–213.
33.
JohnsonSMGrosshansHShingaraJ: RAS is regulated by the let-7 microRNA family. Cell2005; 120: 635–647.
34.
MayrCHemannMTBartelDP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science2007; 315: 1576–1579.
35.
ParkSMShellSRadjabiAR: Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle2007; 6: 2585–2590.
36.
WongTSManOYTsangCM: MicroRNA let-7 suppresses nasopharyngeal carcinoma cells proliferation through downregulating c-Myc expression. J Cancer Res Clin Oncol2011; 137: 415–422.
37.
FedeleMBattistaSKenyonL: Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene2002; 21: 3190–3198.
38.
QianZRAsaSLSiomiH: Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol2009; 22: 431–441.
39.
JohnsonCDEsquela-KerscherAStefaniG: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res2007; 67: 7713–7722.
40.
PengYLaserJShiG: Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res2008; 6: 663–673.
